Clinical Trials Logo

Recurrent Tumor clinical trials

View clinical trials related to Recurrent Tumor.

Filter by:
  • None
  • Page 1

NCT ID: NCT02564198 Recruiting - Clinical trials for Pediatric Solid Tumor

A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors

Start date: December 2015
Phase: Phase 1
Study type: Interventional

The main purpose of this study is to evaluate the safety of the study drug known as ramucirumab in children with recurrent or refractory solid tumors including central nervous system (CNS) tumors.

NCT ID: NCT01956734 Completed - Clinical trials for Glioblastoma Multiforme

Virus DNX2401 and Temozolomide in Recurrent Glioblastoma

Start date: September 2013
Phase: Phase 1
Study type: Interventional

Phase I trial, unicentric, uncontrolled. Intratumoral injection or intramural (into the resected tumor cavity) of DNX2401 into brain tissue will be followed by up to two 28 - day cycles of oral temozolomide (TMZ) in schedule of 7 days on/7 days off to evaluate safety of the combination. Completion of two full cycles of TMZ will be dependent upon tolerance and toxicity. The rationale in using the virus with chemotherapy begins with the lessons learned in many clinical trials in glioblastoma (GBM) about both the great difficulty of treating this disease with monotherapy and the limitations of the therapeutic virus. The best clinical results in recent years have been achieved with combinations of multiple therapeutics efforts, including, maximum resection and chemotherapy, immunotherapy and targeted therapies. There are very strong preclinical data about the synergy of DNX-2401 and TMZ proposed in our trial design. The dose-dense schemes of TMZ like the one we will use, have been developed with the aim to saturate o6-methylguanine-DNA-methyltransferase (MGMT). The published results to date have shown reasonable toxicity albeit with modest efficacy' these schemes are now in phase III trials. In addition, autophagy triggered by TMZ could help viral replication in the tumor cells 11. The last argument in favor of this virus + TMZ combination is the proved efficacy in killing GBM tumor stem cells. In vitro and animals models have shown this combination is much more effective that any of the treatments alone against GBM stem cells and the tumors derived from them.

NCT ID: NCT01493206 Completed - Recurrent Tumor Clinical Trials

A Prospective Single Arm Study of Intraoperative Radiotherapy for Locally Advanced or Recurrent Rectal Cancer

Start date: July 2004
Phase: Phase 2
Study type: Interventional

The hypothesis is that intraoperative radiotherapy for locally advanced or recurrent rectal cancer improve outcomes without causing significant side effects.